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Original Article
Sentinel Lymph Node Scintigraphy and Radioguided Dissection in Breast
Carcinoma: An initial experience at Aga Khan University Hospital
Maseeh uz Zaman1, Shaista Khan1, Riffat Hussain2, M. Nadeem Ahmed2
Dept. of Surgery1, Dept. of Radiology2, Aga Khan University Hospital, Karachi.

Abstract
Objective: To evaluate the efficacy of SLN biopsy using imaging and gamma probe in breast cancer and to
establish this technique at Aga Khan University Hospital.
Methods: Thirty two patients (mean age 33-76 yrs) with operable breast carcinoma (4 with post-neo adjuvant
therapy) with clinically negative axilla were studied. In 28 patients simultaneous axillary dissection was performed. Sentinel lymph nodes (SLN) scintigraphy was performed a day before surgery by injecting Tc-99m
labeled nannocolloid sub-dermally in the peri-areolar region in 24 and peri-tumoral in remaining 8. First lymph
node (LN) to appear to on the scan was labeled as SLN and marked on the skin. Blue dye was also injected in
all patients and blue and hot LN was explored in the axilla using gamma probe.
Results: The sentinel LN was identified in 31 patients (96.9% success rate) while in one patient (3.1%) SLN was
not visualized on the scan (negative study) and this was a post-neo-adjuvant therapy case. The blue dye successfully localized the sentinel LNs in all 32 cases The gamma probe guided localization was successful in all
31 while in one case with post-neo-adjuvant chemotherapy it failed. In 9 out of 32 (28.1%) cases SLN was positive for metastasis and in 6 out of these 9 (66.6%) the SLN was the only metastatic node. This includes the postneo-adjuvant case as well. There was no case of skip metastasis, i.e. negative SNL and positive other axillary
nodes. In remaining 23 (71.9%) cases SLN was negative for metastasis and in all, axilla was free of disease
(NPV of 100%).
Conclusion: Lymphoscintigraphy with gamma probe guided SNL biopsy is safe, simple and highly reliable technique. With blue dye technique it reduces the blindness of the procedure if performed independently but increases the cost. Finally, this can accurately stage the axilla, possibly allowing axillary dissection to be foregone in
patients where the SLN is clear (JPMA 56:153;2006).

Introduction
Axillary dissection has been an essential component
of the surgical treatment of infiltrating breast carcinoma for
a century. The development of imaging and screening
examinations detect small and early stage primary cancers.
In recent years it has been increasingly noted that axillary
dissection finds only healthy lymph nodes.1 Nevertheless it
is mandatory to stage the axilla for obtaining as much prognostic information as possible.
The question, therefore arises, whether lymph node
removal is always necessary in patients with a clinically
negative axilla. The ideal solution would be to diagnose
lymph node involvement through non-invasive techniques
which seem unrealistic at present.2 A promising alternative
appears to be the identification, removal and pathological
examination of the first lymph node that first receives
lymph from the area of breast harbouring the tumor. This
Vol. 56, No. 4, April 2006

lymph node is called sentinel lymph node (SLN). The
assumption is that if SLN is negative, all other axillary
lymph nodes will be negative. The technique of SLN biopsy was first used by Morton et al3,4 in melanoma with
encouraging results. In last few years this technique has
been extensively used in breast cancers with quite promising results and in many centers in the developed countries it
has become an essential part of the breast cancer management. It involves the peri-tumoral or sub dermal injection of
radiolabelled colloid followed by lymphoscintigraphy, and
a gamma ray detecting probe can be used to locate the skin
projection of SLN and assist biopsy.
The purpose of this study was: a) to establish the
lymphoscintigraphy technique in association with gamma
probe for SLN removal and biopsy in breast cancer at Aga
Khan University Hospital, Karachi; b) to compare this technique with blue dye injection in the same patient; and c)
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technique with blue dye injection in the same patient; and c)
compare SLN status with the definitive histologic result of
all axillary lymph nodes after complete axillary dissection.

Patients and Methods
We studied 32 patients with operable breast cancers
diagnosed by physical examination, mammogram and fine
needle aspiration with clinically negative axillary metastasis
(4 with post neo-adjuvant chemotherapy). Exclusion criteria
included lactation, pregnancy, previous excisional biopsy of
breast and clinically palpable axillary lymph nodes. The
average age of the patients was 52 years (range 33-76
years). Tumour size was less than 4.5 cm and 16 were in the
right while remaining 16 in the left breast (14 upper outer,
12 upper inner, 3 lower outer, 1 lower inner and 2 in the central quadrants). In 28 patients simultaneous axillary dissection was performed with either quadrantectomy or modified
radical mastectomy. In remaining 4 patients axillary LN dissection was not done as these patients opted for a secondary
procedure, if SLN biopsy was positive (SLN were negative
for metastasis in all of them).
The day before surgery, 37 MBq (1 mCi) of Tc-99m
Nannocolloid (Nannocol, Amersham) in 2 cc of saline were
injected in 4 aliquots of 0.5 ml sub-dermally in the peri-areolar region in 24 patients and peri-tumoral in remaining 8
patients. Planar scans of the involved breast and axillary
region, in anterior and anterior oblique projections, were
obtained at 10 minutes, 1 hour and 18 hours after the radiocolloid injection. After acquisition of 1 hour image, skin
projection of the first visualized node (defined as the sentinel LN) was marked with a pen while the patient was
supine with arm extended laterally at 90° to the body. To
mark the body contour a rectangular Co-57 flood phantom
source was placed posteriorly.
Radioactivity was detected by the gamma ray probe
(Gamma Sonic®) (Figure 1) transduced into digital readout
and acoustic signals. The intensity and frequency of the
acoustic signals were directly proportional to the level of
radioactivity. The probe was used in the imaging room and
theater pre-operatively to confirmation of the skin projection of the SLN seen on the scintican.
After the primary tumor had been removed, the
gamma probe (in a sterile glove) was used to precisely
locate the skin projection of the node emitting the greatest
radioactivity, using the skin mark as a guide. The skin was
incised directly over this point and using the gamma probe
to guide dissection. The node emitting the highest activity
was placed in the container labeled as sentinel lymph node.
This was followed by complete axillary dissection in 28
patients. In 4 patients simultaneous axillary dissection was
not performed as these patients decided to defer it till
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Figure 1. Gamma ray detecting probe.

Figure 2. Sentinel lymph node containing blue dye explored per-operatively.

histopathology report was available. All removed material
was checked in operating room for radioactivity before
sending it for pathologic examination.
In all patients, 3 ml of blue dye was injected into the
tumor bed immediately after the excision of the primary
nodes using 25 gauge needle. The lymph tract revealed by
the dye was dissected until the blue axillary node was located (Figure 2).
All nodes removed from the axilla (tagged SLN and
from the levels of axilla) were studied using standard protocol and stained with eosin and haematoxylin.
Data is represented as mean ± standard deviation.
Statistical analysis were performed using ANOVA and Chi
Square test were appropriate.

Results
The sentinel LN was identified in 31 patients (96.9%
success rate) while in one patient (3.1%) SLN was not visualized on the scan (negative study) and this was a post-neoadjuvant therapy case. In all these positive cases SLN
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become an essential part of the breast cancer management.
In our study, sentinel LN was successfully localized
with lymphoscintigraphy in 31 patients and failed in one
case with post-neo-adjuvant chemotherapy. The reason for
this false negative result could be heavily embedded node
with metastasis resulting in gross disruption of the lymphatic channels. However, this node was visible with blue dye
per-operatively and revealed metastasis on histological
examination. Therefore, this most likely represents a technique failure resulting from large size of nannocolloid particles (due to clumping) which failed to enter into lymphatic channels.
Figure 3. Sentinel lymph node scintigraphy performed with nannocolloid showing sentinel lymph
node (black arrow) and secondary lymph node (white arrow).

were localized in the ipsilateral axillas. In 20 (64.5%) cases
only one SLN was visualized while in 5 (16.1%) cases two
and in remaining 6 (19.4%) patients three foci were seen on
the scan. When lymphoscintigraphy revealed more than one
node, the first node to become active always showed the
highest uptake in the early and delayed images and was
regarded as the sentinel LN (Figure 3).
Blue disc localization successfully localized the sentinel LNs in all 32 cases (including post-neo-adjuvant case
with no tracer uptake in the axilla on the scan).
Gamma probe guided localization and removal of
SLN was successful in all 31 in whom tracer uptake by axillary LN was observed by lymphoscintigraphy. In one case
with post-neo-adjuvant chemotherapy no LN was detected
with gamma probe, however, SNL was visible with blue dye
per-operatively.
In 9 out of 32 (28.1%) cases sentinel lymph node
was positive for metastasis and in 6 out of these 9 (66.6%)
the sentinel LN was the only metastatic node. This includes
the post-neo-adjuvant case as well. There was no case of
skip metastasis, i.e. negative SNL and positive other axillary nodes (false negative rate was 0%). In remaining 23
(71.9%) cases, SLN was negative for metastasis and in all,
axilla was free of disease (negative predictive value of
100%).

Discussion
Axillary lymph node dissection is an established and
essential component in breast cancer staging, however, it is
associated with unpleasant side effects like cost, surgical
morbidity and lymphoedema. To circumvent these problems, the technique of sentinel lymph node scintigraphy and
radio-guided biopsy of the sentinel LN has been introduced.
Sentinel node biopsy is increasingly being used in clinically lymph node negative, early stage breast cancers.5 In
many developed countries like USA and Europe, this has
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In this study blue dye successfully localized SLN in
all cases (100%) as compared with lymphoscintigraphy
which failed to localize in one case. However, in this procedure axilla is dissected blindly until the blue node, which
may be several centimeters below the incision, is seen. In
our study this procedure was not blind as the SLN was
marked on the skin during scanning and also reconfirmed by
the gamma probe pre-operatively. Furthermore, it is suggested that 30-50 dissections are required to reach the full
competence.4 These limitations certainly outweigh the marginally high success rate of blue dye technique in this study.
In this study, gamma probe guided biopsy successfully identified SLN which is comparable with most of the
published studies.2,6 The concordance between SLN and
axillary LN status was 100%, a false negative rate of 0%
and negative predictive value of 100%. These numbers are
relatively higher than the published data and not statistically significant due to small sample size.
Two decades ago, the treatment of breast cancer was
transformed by the demonstration that conservative surgery
is as effective as mastectomy.1 Today we seem to be on the
threshold of a development that may allow axillary dissection to be foregone in a large percentage of patients. Our
data indicate that SLN biopsy can reliably predict the state
of the axilla, so that when this node is healthy, axillary dissection can be safely avoided. This is important since the
removal of axillary lymph nodes deprives the patient of
lymphatic tissue, which, if healthy, should be retained.
Axillary dissection may have other sequelae, such as
reduced arm motility, reduced skin sensitivity, pain,
lyphoedema and increased susceptibility to infections.7,8
We conclude that lymphoscintigraphy with gamma
probe guided SLN biopsy is a safe, simple and highly reliable technique. When combined with blue dye technique it
reduces the blindness of the procedure if performed independently but increases the cost. Finally, this can accurately
stage the axilla, possibly allowing axillary
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dissection to be foregone in patients where the SLN is clear.
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